Published in J Biol Chem on September 23, 2008
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 1.49
Molecular functions of syndecan-1 in disease. Matrix Biol (2011) 1.47
Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One (2009) 1.46
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One (2009) 1.21
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem (2009) 1.18
Chemical Tumor Biology of Heparan Sulfate Proteoglycans. Curr Chem Biol (2010) 1.17
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem (2010) 1.16
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol (2010) 1.10
Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem (2012) 1.09
The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. Front Oncol (2014) 1.08
Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia (2010) 1.02
Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol (2012) 0.98
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia (2015) 0.98
Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway. Carcinogenesis (2011) 0.96
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget (2016) 0.96
Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem (2009) 0.95
Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem (2012) 0.94
Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol (2013) 0.93
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta (2015) 0.92
Plasma-Mediated Gut Protection After Hemorrhagic Shock is Lessened in Syndecan-1-/- MICE. Shock (2015) 0.92
Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications. Rambam Maimonides Med J (2011) 0.92
Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. Nat Commun (2015) 0.92
Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: a mechanism possibly involved in hereditary multiple exostoses. Am J Pathol (2015) 0.90
Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia (2014) 0.90
Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol (2013) 0.89
Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization. J Biol Chem (2014) 0.89
Gekko-sulfated glycopeptide inhibits tumor angiogenesis by targeting basic fibroblast growth factor. J Biol Chem (2012) 0.86
Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. J Biol Chem (2015) 0.85
Extracellular matrix remodeling in experimental intervertebral disc degeneration. Acta Ortop Bras (2013) 0.84
Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood (2015) 0.83
Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells. Oncotarget (2014) 0.83
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone (2013) 0.83
FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget (2015) 0.82
Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model. Clin Exp Metastasis (2009) 0.82
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis (2016) 0.81
Prognostic value of heparanase expression and cellular localization in oral cancer. Head Neck (2010) 0.81
RGD-xyloside conjugates prime glycosaminoglycans. Glycoconj J (2010) 0.81
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J (2016) 0.80
Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication. Dis Markers (2015) 0.80
Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int (2014) 0.80
Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation. Cancer Microenviron (2010) 0.80
Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity. Oncogene (2015) 0.79
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol (2016) 0.79
Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy. Mol Vis (2016) 0.79
Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. Clin Exp Metastasis (2015) 0.78
Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection. J Gen Virol (2015) 0.78
Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget (2016) 0.77
Myeloma bone disease. J Bone Miner Res (2009) 0.77
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget (2015) 0.76
Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells. PLoS One (2014) 0.76
Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. Am J Pathol (2016) 0.75
Myelomagenesis: capturing early microenvironment changes. Semin Hematol (2011) 0.75
Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity. BMC Cancer (2017) 0.75
Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma. PLoS One (2017) 0.75
Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease. Dig Dis Sci (2016) 0.75
Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment. Oncotarget (2017) 0.75
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 21.15
Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol (1999) 5.93
Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell (2002) 4.89
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol (2000) 2.87
Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell (1998) 2.75
Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev (2007) 2.58
Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52
Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol (2000) 2.33
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem (2003) 2.08
Heparanase as mediator of angiogenesis: mode of action. FASEB J (2001) 2.04
Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res (2006) 2.02
Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med (2005) 1.93
The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des (2004) 1.93
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem (2004) 1.78
Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev (1996) 1.77
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res (2007) 1.65
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. J Cell Biol (2006) 1.62
Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol (2002) 1.57
Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood (2000) 1.54
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood (2000) 1.52
Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol (2005) 1.51
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood (2002) 1.50
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res (2002) 1.46
Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem (2004) 1.43
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer (2006) 1.42
The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology (2006) 1.39
Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood (2004) 1.38
Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry (2000) 1.37
Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells (2007) 1.35
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood (1993) 1.34
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther (2005) 1.33
Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma (1993) 1.27
Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene (2001) 1.26
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer (2007) 1.23
Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem (2005) 1.22
Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry (2004) 1.21
Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer (2001) 1.17
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol (1997) 1.17
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood (2002) 1.15
FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia (2006) 1.11
Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res (2001) 1.09
Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells. Matrix Biol (2007) 0.97
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br J Haematol (2003) 0.96
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol (2007) 0.95
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia (2004) 0.93
Cloning, expression, and purification of mouse heparanase. Protein Expr Purif (2002) 0.92
Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica (2008) 0.91
Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol (2006) 0.91
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol (2000) 0.91
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol (2007) 0.90
Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer (2002) 0.88
Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol (2004) 0.85
Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis (2004) 0.83
Containing pandemic influenza with antiviral agents. Am J Epidemiol (2004) 12.82
Containing bioterrorist smallpox. Science (2002) 7.62
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
A polymer tandem solar cell with 10.6% power conversion efficiency. Nat Commun (2013) 4.48
Do birth cohorts matter? Age-period-cohort analyses of the obesity epidemic in the United States. Soc Sci Med (2009) 3.87
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol (2006) 3.48
Neuronal basis of age-related working memory decline. Nature (2011) 3.15
Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A (2010) 2.94
High-throughput solution processing of large-scale graphene. Nat Nanotechnol (2008) 2.93
Patterning organic single-crystal transistor arrays. Nature (2006) 2.80
The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci (2012) 2.71
A practical comparison of de novo genome assembly software tools for next-generation sequencing technologies. PLoS One (2011) 2.55
NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron (2013) 2.46
Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity (2010) 2.44
Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system. Pain (2012) 2.34
Engaging in an auditory task suppresses responses in auditory cortex. Nat Neurosci (2009) 2.34
Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry (2011) 2.33
Murine B7-H3 is a negative regulator of T cells. J Immunol (2004) 2.33
Planar heterojunction perovskite solar cells via vapor-assisted solution process. J Am Chem Soc (2013) 2.32
Containing a large bioterrorist smallpox attack: a computer simulation approach. Int J Infect Dis (2006) 2.29
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Protein 4.1R-dependent multiprotein complex: new insights into the structural organization of the red blood cell membrane. Proc Natl Acad Sci U S A (2008) 2.18
Association of the beta2-adrenergic receptor gene with essential hypertension in the non-Han Chinese Yi minority human population. J Hypertens (2006) 2.16
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Mechanical Deformation Behavior of Nonpolar GaN Thick Films by Berkovich Nanoindentation. Nanoscale Res Lett (2009) 1.95
Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci (2010) 1.93
Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer (2009) 1.92
Spectrins and ankyrinB constitute a specialized paranodal cytoskeleton. J Neurosci (2006) 1.90
Practical chemical sensors from chemically derived graphene. ACS Nano (2009) 1.85
Development of effective quantum mechanical/molecular mechanical (QM/MM) methods for complex biological processes. J Phys Chem B (2006) 1.83
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation (2005) 1.82
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Klf4 interacts directly with Oct4 and Sox2 to promote reprogramming. Stem Cells (2009) 1.79
Digital memory device based on tobacco mosaic virus conjugated with nanoparticles. Nat Nanotechnol (2006) 1.79
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol (2004) 1.75
Dispersal state of multiwalled carbon nanotubes elicits profibrogenic cellular responses that correlate with fibrogenesis biomarkers and fibrosis in the murine lung. ACS Nano (2011) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
Plasmonic polymer tandem solar cell. ACS Nano (2011) 1.68
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem (2005) 1.66
Polyaniline nanofiber/gold nanoparticle nonvolatile memory. Nano Lett (2005) 1.64
Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem (2005) 1.64
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61
Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A (2009) 1.61
Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol (2009) 1.60
LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PLoS One (2012) 1.59
Plant DNA barcoding: from gene to genome. Biol Rev Camb Philos Soc (2014) 1.56
Controllable self-induced passivation of hybrid lead iodide perovskites toward high performance solar cells. Nano Lett (2014) 1.54
The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause (2011) 1.52
Low-temperature solution processing of graphene-carbon nanotube hybrid materials for high-performance transparent conductors. Nano Lett (2009) 1.50
Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol Ther (2011) 1.50
Oncomodulin links inflammation to optic nerve regeneration. Proc Natl Acad Sci U S A (2009) 1.50
Long-term in vivo biodistribution imaging and toxicity of polyacrylic acid-coated upconversion nanophosphors. Biomaterials (2010) 1.50
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
Surgical management and evaluation of prognostic factors influencing postoperative visual outcome of suprasellar meningiomas. World Neurosurg (2011) 1.49
The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and RhoA. J Biol Chem (2005) 1.49
Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol (2008) 1.48
Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials (2011) 1.48
Dynamic Network Connectivity: A new form of neuroplasticity. Trends Cogn Sci (2010) 1.48
Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell differentiation by regulating Nanog gene expression. J Biol Chem (2010) 1.48
Surface charge and cellular processing of covalently functionalized multiwall carbon nanotubes determine pulmonary toxicity. ACS Nano (2013) 1.47
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics (2009) 1.46
Single-crystal linear polymers through visible light-triggered topochemical quantitative polymerization. Science (2014) 1.45
Autophagy negatively regulates cancer cell proliferation via selectively targeting VPRBP. Clin Sci (Lond) (2013) 1.45
Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis (2009) 1.44
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res (2010) 1.44
MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res (2010) 1.43
Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens (2012) 1.43
Cardiovascular responses during percutaneous radiofrequency thermocoagulation therapy in primary trigeminal neuralgia. J Neurosurg Anesthesiol (2008) 1.43
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
Pluronic F108 coating decreases the lung fibrosis potential of multiwall carbon nanotubes by reducing lysosomal injury. Nano Lett (2012) 1.40
Retracted Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine (Baltimore) (2014) 1.40
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Nanowire-based sensors. Small (2010) 1.39
Programmable polymer thin film and non-volatile memory device. Nat Mater (2004) 1.39
Mechanochemical coupling in the myosin motor domain. II. Analysis of critical residues. PLoS Comput Biol (2006) 1.39
Mapping spread and risk of avian influenza A (H7N9) in China. Sci Rep (2013) 1.38
Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood (2004) 1.38
Phenotypically distinct B cell development pathways map to the three B cell lineages in the mouse. Proc Natl Acad Sci U S A (2006) 1.38
The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood (2003) 1.37
An efficient triple-junction polymer solar cell having a power conversion efficiency exceeding 11%. Adv Mater (2014) 1.35
Low-temperature solution-processed perovskite solar cells with high efficiency and flexibility. ACS Nano (2014) 1.35
New forecasting methodology indicates more disease and earlier mortality ahead for today's younger Americans. Health Aff (Millwood) (2011) 1.34
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res (2006) 1.33
A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One (2011) 1.32
Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice. Hepatology (2009) 1.31
DNA gridiron nanostructures based on four-arm junctions. Science (2013) 1.31
Social Change and Socioeconomic Disparities in Health over the Life Course in China: A Cohort Analysis. Am Sociol Rev (2010) 1.31
Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res (2011) 1.30
Transcriptional regulator Id2 controls survival of hepatic NKT cells. Proc Natl Acad Sci U S A (2009) 1.30
Where is the spike generator of the cochlear nerve? Voltage-gated sodium channels in the mouse cochlea. J Neurosci (2005) 1.28
Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev (2012) 1.28
Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis (2007) 1.27